检索结果 - Leip, Eric

Bosutinib in Combination With the Aromatase Inhibitor Letrozole: A Phase II Trial in Postmenopausal Women Evaluating First-Line Endocrine Therapy in Locally Advanced or Metastatic... 由 Moy, Beverly, Neven, Patrick, Lebrun, Fabienne, Bellet, Meritxell, Xu, Binghe, Sarosiek, Tomasz, Chow, Louis, Goss, Paul, Zacharchuk, Charles, Leip, Eric, Turnbull, Kathleen, Bardy-Bouxin, Nathalie, Duvillié, Ladan, Láng, István

获取全文 获取全文 获取全文

Bosutinib in Combination With the Aromatase Inhibitor Exemestane: A Phase II Trial in Postmenopausal Women With Previously Treated Locally Advanced or Metastatic Hormone Receptor-P... 由 Moy, Beverly, Neven, Patrick, Lebrun, Fabienne, Bellet, Meritxell, Xu, Binghe, Sarosiek, Tomasz, Chow, Louis, Goss, Paul, Zacharchuk, Charles, Leip, Eric, Turnbull, Kathleen, Bardy-Bouxin, Nathalie, Duvillié, Ladan, Láng, István

获取全文 获取全文 获取全文

Long‐term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib 由 Cortes, Jorge E., Khoury, Hanna J., Kantarjian, Hagop M., Lipton, Jeff H., Kim, Dong‐Wook, Schafhausen, Philippe, Matczak, Ewa, Leip, Eric, Noonan, Kay, Brümmendorf, Tim H., Gambacorti‐Passerini, Carlo

获取全文 获取全文 获取全文

Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure 由 Khoury, H. Jean, Cortes, Jorge E., Kantarjian, Hagop M., Gambacorti-Passerini, Carlo, Baccarani, Michele, Kim, Dong-Wook, Zaritskey, Andrey, Countouriotis, Athena, Besson, Nadine, Leip, Eric, Kelly, Virginia, Brümmendorf, Tim H.

获取全文 获取全文 获取全文

Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors 由 Kantarjian, Hagop M., Cortes, Jorge E., Kim, Dong-Wook, Khoury, H. Jean, Brümmendorf, Tim H., Porkka, Kimmo, Martinelli, Giovanni, Durrant, Simon, Leip, Eric, Kelly, Virginia, Turnbull, Kathleen, Besson, Nadine, Gambacorti-Passerini, Carlo

获取全文 获取全文 获取全文

Long‐term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors 由 Gambacorti‐Passerini, Carlo, Kantarjian, Hagop M., Kim, Dong‐Wook, Khoury, Hanna J., Turkina, Anna G., Brümmendorf, Tim H., Matczak, Ewa, Bardy‐Bouxin, Nathalie, Shapiro, Mark, Turnbull, Kathleen, Leip, Eric, Cortes, Jorge E.

获取全文 获取全文 获取全文

Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study 由 Gambacorti-Passerini, Carlo, Cortes, Jorge E., Lipton, Jeff H., Kantarjian, Hagop M., Kim, Dong-Wook, Schafhausen, Philippe, Crescenzo, Rocco, Bardy-Bouxin, Nathalie, Shapiro, Mark, Noonan, Kay, Leip, Eric, DeAnnuntis, Liza, Brümmendorf, Tim H., Khoury, H. Jean

获取全文 获取全文 获取全文

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome–positive chronic myeloid leukemia patients with resistance or intolerance to imatinib 由 Cortes, Jorge E., Kantarjian, Hagop M., Brümmendorf, Tim H., Kim, Dong-Wook, Turkina, Anna G., Shen, Zhi-Xiang, Pasquini, Ricardo, Khoury, H. Jean, Arkin, Steven, Volkert, Angela, Besson, Nadine, Abbas, Richat, Wang, Junyuan, Leip, Eric, Gambacorti-Passerini, Carlo

获取全文 获取全文 获取全文

Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib 由 Cortes, Jorge E., Khoury, H. Jean, Kantarjian, Hagop, Brümmendorf, Tim H., Mauro, Michael J., Matczak, Ewa, Pavlov, Dmitri, Aguiar, Jean M., Fly, Kolette D., Dimitrov, Svetoslav, Leip, Eric, Shapiro, Mark, Lipton, Jeff H., Durand, Jean-Bernard, Gambacorti-Passerini, Carlo

获取全文 获取全文 获取全文

Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial 由 Cortes, Jorge E., Gambacorti-Passerini, Carlo, Deininger, Michael W., Mauro, Michael J., Chuah, Charles, Kim, Dong-Wook, Dyagil, Irina, Glushko, Nataliia, Milojkovic, Dragana, le Coutre, Philipp, Garcia-Gutierrez, Valentin, Reilly, Laurence, Jeynes-Ellis, Allison, Leip, Eric, Bardy-Bouxin, Nathalie, Hochhaus, Andreas, Brümmendorf, Tim H.

获取全文 获取全文 获取全文

Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study 由 Hochhaus, Andreas, Gambacorti-Passerini, Carlo, Abboud, Camille, Gjertsen, Bjørn Tore, Brümmendorf, Tim H., Smith, B. Douglas, Ernst, Thomas, Giraldo-Castellano, Pilar, Olsson-Strömberg, Ulla, Saussele, Susanne, Bardy-Bouxin, Nathalie, Viqueira, Andrea, Leip, Eric, Russell-Smith, T. Alexander, Leone, Jocelyn, Rosti, Gianantonio, Watts, Justin, Giles, Francis J.

获取全文 获取全文 获取全文

Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial 由 Brümmendorf, Tim H., Cortes, Jorge E., Milojkovic, Dragana, Gambacorti-Passerini, Carlo, Clark, Richard E., le Coutre, Philipp, Garcia-Gutierrez, Valentin, Chuah, Charles, Kota, Vamsi, Lipton, Jeffrey H., Rousselot, Philippe, Mauro, Michael J., Hochhaus, Andreas, Hurtado Monroy, Rafael, Leip, Eric, Purcell, Simon, Yver, Anne, Viqueira, Andrea, Deininger, Michael W.

获取全文 获取全文 获取全文

Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up 由 Gambacorti-Passerini, Carlo, Brümmendorf, Tim H, Kim, Dong-Wook, Turkina, Anna G, Masszi, Tamas, Assouline, Sarit, Durrant, Simon, Kantarjian, Hagop M, Khoury, H Jean, Zaritskey, Andrey, Shen, Zhi-Xiang, Jin, Jie, Vellenga, Edo, Pasquini, Ricardo, Mathews, Vikram, Cervantes, Francisco, Besson, Nadine, Turnbull, Kathleen, Leip, Eric, Kelly, Virginia, Cortes, Jorge E

获取全文 获取全文 获取全文